Savior Lifetec (4167.TWO) stock: key figures, P/E, revenue and dividend

Health Care · Biotechnology · Taiwan · ISIN TW0004167002

Price
19.05 TWD
Market cap
6.32 bn TWD
P/E (2025)
11.75
P/S (2025)
5.26
Dividend yield
4.22 %
Net margin
44.72 %
Return on equity (ROE)
14.22 %
Return on assets (ROA)
12.84 %

Savior Lifetec financials

Fiscal year20242025
Revenue1.22 bn TWD1.20 bn TWD
Gross profit346.76 m TWD423.41 m TWD
Operating income118.90 m TWD198.24 m TWD
EBIT186.88 m TWD539.50 m TWD
Net income182.38 m TWD537.45 m TWD
Diluted EPS – continuing operations0.54 TWD1.62 TWD

Full history since 2011, charts and your own formulas

This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.

Sign up for freeOpen interactive view

About Savior Lifetec

Savior Lifetec Corporation engages in the research, development, design, manufacture, and sale of carbapenem generics in the Americas, Asia, Taiwan, Europe, and internationally. The company offers injection generics, controlled-release generics, the development of new dosage forms and drugs, and the APIs, excipients, intermediates, and dosage forms. It also provides medicine manufacturer technology and services. In addition, the company sells antibacterial raw materials and injectables. Savior Lifetec Corporation was founded in 1993 and is headquartered in Tainan City, Taiwan.

More stocks

All stocks →

Not investment advice. All data without warranty, price as of 12.11.2026. Details in the risk notice.